Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Block listing Interim Review

23 Nov 2020 08:59

RNS Number : 1549G
GlaxoSmithKline PLC
23 November 2020
 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc 2009 Deferred Annual Bonus Plan

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

135,376

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

74,556

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

60,820

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - Ordinary Shares

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

254,091

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

32,278

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

221,813

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline 2009 Share Option Plan - ADS

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

4,692,680

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

64,816

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

4,627,864

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

 

BLOCK LISTING SIX MONTHLY RETURN

 

 

Date: 23 November 2020

 

Name of applicant:

GlaxoSmithKline plc

Name of scheme:

GlaxoSmithKline plc Share Save Plan 2012

Period of return:

From:

1 May 2020

To:

31 October 2020

Balance of unallotted securities under scheme(s) from previous return:

1,447,405

Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

169,776

Equals: Balance under scheme(s) not yet issued/allotted at end of period:

1,277,629

     

 

Name of contact:

Victoria Whyte

Telephone number of contact:

020 8047 5000

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRKZMZMRFRGGZG
Date   Source Headline
18th Jan 20245:00 pmRNSHolding(s) in Company
17th Jan 20243:30 pmRNSDirector/PDMR Shareholding
17th Jan 20247:00 amRNSGSK completes sale of shares in Haleon plc
16th Jan 20244:40 pmRNSGSK announces intention to sell shares in Haleon
16th Jan 20243:30 pmRNSDirector/PDMR Shareholding
10th Jan 20247:00 amRNSNucala approved in China for use in severe asthma
9th Jan 20247:00 amRNSGSK enters agreement to acquire Aiolos Bio
2nd Jan 20243:00 pmRNSTotal Voting Rights
21st Dec 20233:30 pmRNSDirector/PDMR Shareholding
20th Dec 20234:44 pmRNSPublication of EMTN Suppl.Prospcts
18th Dec 20237:00 amRNSJemperli plus Zejula Trial Meets Endpoint
13th Dec 20233:30 pmRNSDirector/PDMR Shareholding
12th Dec 20237:00 amRNSJapan accepts Arexvy filing for at risk adults
11th Dec 20237:00 amRNSJemperli plus chemotherapy EU authorisation
4th Dec 20233:02 pmRNSGSK publishes provisional 2024 dividend dates
1st Dec 20233:00 pmRNSTotal Voting Rights
30th Nov 20239:00 amRNSBlock Listing Application
29th Nov 20233:23 pmRNSHolding(s) in Company
27th Nov 20237:00 amRNSGSK announces positive DREAMM-7 headline results
21st Nov 20233:30 pmRNSDirector/PDMR Shareholding
15th Nov 20233:00 pmRNSBlock listing Interim Review
13th Nov 20233:30 pmRNSDirector/PDMR Shareholding
13th Nov 20237:00 amRNSGSK receives positive CHMP opinion for momelotinib
1st Nov 20233:00 pmRNSTotal Voting Rights
1st Nov 20237:00 amRNS3rd Quarter Results
30th Oct 20237:00 amRNSJemperli trial meets overall survival endpoint
26th Oct 20237:00 amRNSNMPA approves Vocabria+Rekambys in China
25th Oct 20233:30 pmRNSDirector/PDMR Shareholding
25th Oct 20237:00 amRNSNew data for Arexvy, GSK’s RSV vaccine
20th Oct 20233:30 pmRNSDirector/PDMR Shareholding
18th Oct 20233:30 pmRNSDirector/PDMR Shareholding
17th Oct 20233:30 pmRNSDirector/PDMR Shareholding
16th Oct 20237:00 amRNSJemperli plus chemotherapy positive CHMP opinion
13th Oct 20233:30 pmRNSDirector/PDMR Shareholding
12th Oct 20233:30 pmRNSDirector/PDMR Shareholding
11th Oct 20237:00 amRNSZantac (ranitidine) litigation
10th Oct 202311:00 amRNSHolding(s) in Company
9th Oct 20237:00 amRNSGSK and Zhifei announce vaccine partnership
6th Oct 20237:00 amRNSGSK completes sale of shares in Haleon plc
5th Oct 20234:46 pmRNSGSK announces intention to sell shares in Haleon
2nd Oct 20233:00 pmRNSTotal Voting Rights
27th Sep 20233:00 pmRNSDirectorate Change
25th Sep 20237:00 amRNSGSK RSV vaccine for older adults approved in Japan
21st Sep 20233:30 pmRNSDirector/PDMR Shareholding
19th Sep 20237:00 amRNSApretude for PrEP receives EMA approval
18th Sep 20237:00 amRNSFDA approves Ojjaara (momelotinib)
13th Sep 20233:30 pmRNSDirector/PDMR Shareholding
11th Sep 20233:30 pmRNSDirector/PDMR Shareholding
11th Sep 20237:00 amRNSMomelotinib filing accepted in Japan
1st Sep 20233:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.